- Home
- NXE vs CRL Comparison
NXE vs CRL Comparison
Compare NXE & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXE | CRL |
|---|---|---|
| Founded | 2011 | 1947 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.3B |
| IPO Year | 2017 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NXE | CRL |
|---|---|---|
| Price | $12.10 | $175.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $197.58 |
| AVG Volume (30 Days) | ★ 7.5M | 1.3M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | N/A | $2.11 |
| Revenue Next Year | N/A | $2.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $3.91 | $91.86 |
| 52 Week High | $13.96 | $228.88 |
Technical Indicators
Market Signals| Indicator | NXE | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 45.16 |
| Support Level | $7.79 | $145.97 |
| Resistance Level | $13.96 | $182.81 |
| Average True Range (ATR) | 0.65 | 8.05 |
| MACD | -0.06 | 2.56 |
| Stochastic Oscillator | 44.01 | 80.86 |
Price Performance
Historical ComparisonAbout NXE Nexgen Energy Ltd.
NexGen Energy Ltd is an exploration and development entity engaged in acquiring, evaluating, and developing uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin.
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.